Use of common medications and breast cancer risk

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 7, 2008, Pages 1564-1595

  Moysich, Kirsten B ^a   Beehler, Gregory P ^b   Zirpoli, Gary ^a,c   Choi, Ji Yeob ^a   Baker, Julie A ^d  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b VA WESTERN NEW YORK HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d WOMEN AND INFANTS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMITRIPTYLINE; AMOXAPINE; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; CLOMIPRAMINE; CYCLOOXYGENASE 2 INHIBITOR; DESIPRAMINE; DOXEPIN; DRUG RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; IMIPRAMINE; MACROLIDE; MAPROTILINE; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; PAROXETINE; PENICILLIN G; PLANT MEDICINAL PRODUCT; PROTRIPTYLINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TESMILIFENE; TETRACYCLINE; TETRACYCLINE DERIVATIVE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; UNINDEXED DRUG;

BREAST CANCER; BREAST CARCINOGENESIS; CANCER EPIDEMIOLOGY; CANCER RISK; CLINICAL TRIAL; DRUG EXPOSURE; DRUG MEGADOSE; DRUG USE; EVIDENCE BASED MEDICINE; GENOTOXICITY; HUMAN; INFECTION; LOW DRUG DOSE; NONHUMAN; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RISK REDUCTION;

BREAST NEOPLASMS; FEMALE; HUMANS; INCIDENCE; NONPRESCRIPTION DRUGS; PRESCRIPTION DRUGS; RISK FACTORS; WORLD HEALTH;

EID: 53549099404     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-07-2828     Document Type: Review

References (129)

1. Kaufman DWS, Kelly JPMS, Rosenberg LS, Anderson TERN, Mitchell AAMD. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone Survey. JAMA Index Issue 2002;287:337-44. Available from: http://www.jama.com.
2. Patterns of medication use in the United States - a report from the Slone Survey. 2005.
3. Velicer CM, Lampe JW, Heckbert SR, Potter JD, Taplin SH. Hypothesis: is antibiotic use associated with breast cancer? Cancer Causes Control 2003;14:739-47.
4. Adlercreutz H. Evolution, nutrition, intestinal microflora, and prevention of cancer: a hypothesis. Proc Soc Exp Biol Med 1998;217:241-6.
5. Rowland I, Wiseman H, Sanders T, Adlercreutz H, Bowey E. Metabolism of oestrogens and phytoestrogens: role of the gut microflora. Biochem Soc Trans 1999;27:304-8.
6. Shapiro TA, Fahey JW, Wade KL, Stephenson KK, Talalay P. Human metabolism and excretion of cancer chemoprotective glucosinolates and isothiocyanates of cruciferous vegetables. Cancer Epidemiol Biomarkers Prev 1998;7:1091-100.
7. Johnson SA, Nicolson SW, Jackson S. The effect of different oral antibiotics on the gastrointestinal microflora of a wild rodent (Aethomys namaquensis). Comp Biochem Physiol A Mol Integr Physiol 2004;138:475.
8. Sullivan A, Edlund C, Nord CE. Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect Dis 2001;1:101.
9. Ianaro A, Ialenti A, Maffia P, et al. Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exp Ther 2000;292:156-63.
10. Purohit A, Newman SP, Reed MJ. The role of cytokines in regulating estrogen synthesis: implications for the etiology of breast cancer. Breast Cancer Res 2002;4:65-9.
11. Reed MJ, Purohit A. Aromatase regulation and breast cancer. Clin Endocrinol 2001;54:563-71.
12. Friedman GD, Oestreicher N, Chan J, Quesenberry CP, Jr., Udaltsova N, Habel LA. Antibiotics and risk of breast cancer: up to 9 years of follow-up of 2.1 million women. Cancer Epidemiol Biomarkers Prev 2006;15:2102-6.
13. Velicer CM, Heckbert SR, Rutter C, Lampe JW, Malone K. Association between antibiotic use prior to breast cancer diagnosis and breast tumor characteristics (United States). Cancer Causes Control 2006;17:307-13.
14. Lawlor DA, Juni P, Ebrahim S, Egger M. Systematic review of the epidemiologic and trial evidence of an association between antidepressant medication and breast cancer. J Clin Epidemiol 2003;:155-63.
15. Danielson DA, Jick H, Hunter JR, Stergachis A, Madsen S. Nonestrogenic drugs and breast cancer. Am J Epidemiol 1982;116:329-32.
16. Wang PS, Walker AM, Tsuang MT, Orav EJ, Levin R, Avorn J. Antidepressant use and the risk of breast cancer: a non-association. J Clin Epidemiol 2001;54:728-34.
17. Kato I, Zeleniuch-Jacquotte A, Toniolo PG, Akhmedkhanov A, Koenig K, Shore RE. Psychotropic medication use and risk of hormone-related cancers: the New York University Women's Health Study. J Public Health Med 2000;22:155-60.
18. Weiss S, McFarland B, Burkhart G, Ho P. Cancer recurrences and secondary primary cancers after use of antihistamines or antidepressants. Clin Pharmacol Ther 1998;63:594-9.
19. Moorman PG, Grubber J, Millikan R, Newman B. Antidepressant medications and their association with invasive breast cancer and carcinoma in situ of the breast. Epidemiology 2003;14:307-14.
20. Brandes LJ, Arron RJ, Bogdanovic RP, et al. Stimulation of malignant growth in rodents by antidepressant drugs at clinically relevant doses. Cancer Res 1992;52:3796-800.
21. Volpe DA, Ellison CD, Parchment RE, Grieshaber CK, Faustino PJ. Effects of amitriptyline and fluoxetine upon the in vitro proliferation of tumor cell lines. J Exp Ther Oncol 2003;3:169-84.
22. Sharpe C, Collet JP, Belzile E, Hanley J, Boivin JF. The effects of tricyclic antidepressants on breast cancer risk. Br J Cancer 2002;86:92-7.
23. Fulton-Kehoe D, Rossing MA, Rutter C, Mandelson M, Weiss N. Use of antidepressant medications in relation to the incidence of breast cancer. Br J Cancer 2006;94:1071-8.
24. Lokugamage A, Hotopf M, Hardy R, et al. Breast cancer in relation to childhood parental divorce and early adult psychiatric disorder in a British birth cohort. Psychol Med 2006;36:1307-12.
25. Chien C, Li C, Heckbert SR, Malone K, Boudreau DM, Daling JR. Antidepressant use and breast cancer risk. Breast Cancer Res Treat 2006;95:131-40.
26. Dulchin MC, Oquendo MA, Malone KM, Ellis SP, Li S, Mann JJ. Prolactin response to DL-fenfluramine challenge before and after treatment with paroxetine. Neuropsychopharmacology 2001;25:395-401.
27. Molitch ME. Medication-induced hyperprolactinemia. Mayo Clin Proc 2005;80:1050-7.
28. Denoyelle C, Vasse M, Korner M, et al. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis 2001;22:1139-48.
29. Muck AO, Seeger H, Wallwiener D. Inhibitory effect of statins on the proliferation of human breast cancer cells. Int J Clin Pharmacol Ther 2004;42:695-700.
30. Mueck AO, Seeger H, Wallwiener D. Effect of statins combined with estradiol on the proliferation of human receptor-positive and receptor-negative breast cancer cells. Menopause 2003;10:332-6.
31. Seeger H, Wallwiener D, Mueck AO. Statins can inhibit proliferation of human breast cancer cells in vitro. Exp Clin Endocrinol Diabetes 2003;111:47-8.
32. Alonso DF, Farina HG, Skilton G, Gabri MR, De Lorenzo MS, Gomez DE. Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis. Breast Cancer Res Treat 1998;50:83-93.
33. Sleijfer S, van der Gaast A, Planting AS, Stoter G, Verweij J. The potential of statins as part of anti-cancer treatment. Eur J Cancer 2005;41:516-22.
34. Yao CJ, Lai GM, Chan CF, Cheng AL, Yang YY, Chuang SE. Dramatic synergistic anticancer effect of clinically achievable doses of lovastatin and troglitazone. Int J Cancer 2006;118:773-9.
35. Feleszko W, Jalili A, Olszewska D, et al. Synergistic interaction between highly specific cyclooxygenase-2 inhibitor, MF-tricyclic and lovastatin in murine colorectal cancer cell lines. Oncol Rep 2002;9:879-85.
36. Steingart A, Cotterchio M, Kreiger N, Sloan M. Antidepressant medication use and breast cancer risk: a case-control study. Int J Epidemiol 2003;32:961-6.
37. Coogan PF, Palmer JR, Strom BL, Rosenberg L. Use of selective serotonin reuptake inhibitors and the risk of breast cancer. Am J Epidemiol 2005;162:835-8.
38. Gonzalez-Perez A, Garcia Rodriguez L. Breast cancer risk among users of antidepressant medications. Epidemiology 2005;16:101-5.
39. Haque R, Enger S, Chen W, Petitti D. Breast cancer risk in a large cohort of female antidepressant medication users. Cancer Lett 2005;221:61-5.
40. Newman TB, Hulley SB. Carcinogenicity of lipid-lowering drugs [see comment]. JAMA 1996;275:55-60.
41. Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM. Statins and cancer prevention. Nat Rev Cancer 2005;5:930-42.
42. 1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53. Oncogene 1998;17:2393-402.
43. Katz MS, Minsky BD, Saltz LB, Riedel E, Chessin DB, Guillem JG. Association of statin use with a pathologic complete response to neoadjuvant chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys 2005;62:1363-70.
44. Feleszko W, Zagozdzon R, Golab J, Jakobisiak M. Potentiated antitumour effects of cisplatin and lovastatin against MmB16 melanoma in mice. Eur J Cancer 1998;34:406-11.
45. Gonzalez-Perez A, Ronquist G, Garcia Rodriguez LA. Breast cancer incidence and use of antihypertensive medication in women. Pharmacoepidemiol Drug Saf 2004;:581-5.
46. Jick H, Jick S, Derby LE, Vasilakis C, Myers MW, Meier CR. Calcium-channel blockers and risk of cancer. Lancet 1997;:525-8.
47. Meier CR, Derby LE, Jick SS, Jick H. Angiotensin-converting enzyme inhibitors, calcium channel blockers, and breast cancer. Arch Int Med 2000;:349-53.
48. Olsen JH, Sorensen HT, Friis S, et al. Cancer risk in users of calcium channel blockers. Hypertension 1997;:1091-4.
49. Sorensen HT, Olsen JH, Mellemkjaer L, et al. Cancer risk and mortality in users of calcium channel blockers. A cohort study. Cancer 2000;:165-70.
50. Rosenberg LS, Rao RSMS, Palmer JRS, et al. Calcium channel blockers and the risk of cancer. JAMA 1998;:1000-4.
51. Michels KB, Rosner BA, Walker AM, et al. Calcium channel blockers, cancer incidence, and cancer mortality in a cohort of U.S. women: the Nurses' Health Study. Cancer 1998;:2003-7.
52. Peeters P, Van Noord P, Hoes A, Grobbee DE. Hypertension, antihypertensive drugs, and mortality from cancer among women. J Hypertens 1998;16:941-7.
53. Fitzpatrick AL, Daling JR, Furberg CD, Kronmal RA, Weissfeld JL. Use of calcium channel blockers and breast carcinoma risk in postmenopausal women. Cancer 1997;:1438-47.
54. Coogan PF, Rosenberg L, Palmer JR, Strom BL, Zauber AG, Shapiro S. Statin use and the risk of breast and prostate cancer [see comment]. Epidemiology 2002;:262-7.
55. Coogan PF, Rosenberg L, Strom BL. Statin use and the risk of 10 cancers. Epidemiology 2007;18:213-9.
56. Boudreau DM, Gardner JS, Malone KE, Heckbert SR, Blough DK, Daling JR. The association between 3-hydroxy-3-methylglutaryl coenzyme Ainhibitor use and breast carcinoma risk among postmenopausal women: a case-control study. Cancer 2004;100:2308-16.
57. Eliassen AH, Colditz GA, Rosner B, Willett WC, Hankinson SE. Serum lipids, lipid-lowering drugs, and the risk of breast cancer. Arch Int Med 2005;:2264-71.
58. Cauley JA, McTiernan A, Rodabough RJ, et al. Statin use and breast cancer: prospective results from the Women's Health Initiative. J Natl Cancer Inst 2006;:700-7.
59. Cauley JA, Zmuda JM, Lui LY, et al. Lipid-lowering drug use and breast cancer in older women: a prospective study. J Womens Health 2003;:749-56.
60. Bonovas S, Filioussi K, Tsavaris N, Sitaras N. Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. J Clin Oncol 2005;23:48606-12.
61. Dale K, Coleman C, Henyan N, Kluger J, White C. Statins and cancer risk: a meta-analysis. JAMA 2006;295:74-80.
62. Pahor M, Guralnik JM, Salive ME, Corti M-C, Carbonin P, Havlik RJ. Do calcium channel blockers increase the risk of cancer? Am J Hypertens 1996;9:695.
63. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002;94:252-66.
64. Han EK, Arber N, Yamamoto H, et al. Effects of sulindac and its metabolites on growth and apoptosis in human mammary epithelial and breast carcinoma cell lines. Breast Cancer Res Treat 1998;48:195-203.
65. Coogan PF, Rao S, Rosenberg L, et al. The relationship of nonsteroidal anti-inflammatory drug use to the risk of breast cancer. Prev Med 1999;29:72-6.
66. Mason RP. Effects of calcium channel blockers on cellular apoptosis. Cancer 1999;85:2093-102.
67. Correale P, Tagliaferri P, Celio L, Genua G, Montagnani S, Bianco AR. Verapamil upregulates sensitivity of human colon and breast cancer cells to LAK-cytotoxicity in vitro. Eur J Cancer 1991;27:1393-5.
68. Taylor JM, Simpson RU. Inhibition of cancer cell growth by calcium channel antagonists in the athymic mouse. Cancer Res 1992;52:2413-8.
69. Matsusaka T, Fogo A, Ichikawa I. Targeting the genes of angiotensin receptors. Semin Nephrol 1997;17:396-403.
70. Fernandez LA, Twickler J, Mead A. Neovascularization produced by angiotensin II. J Lab Clin Med 1985;105:141-5.
71. Hii SI, Nicol DL, Gotley DC, Thompson LC, Green MK, Jonsson JR. Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma. Br J Cancer 1998;77:880-3.
72. Volpert OV, Ward WF, Lingen MW, et al. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats [see comment]. J Clin Invest 1996;98:671-9.
73. Yoshiji H, Kuriyama S, Noguchi R, Fukui H. Angiotensin-I converting enzyme inhibitors as potential anti-angiogenic agents for cancer therapy. Curr Cancer Drug Targets 2004;4:555-67.
74. Yasumatsu R, Kuratomi Y, Nakashima T, Masuda M, Yamamoto T. Cyclin D1 expression does not effect cell proliferation in adenoid cystic carcinoma of the salivary gland. Eur Arch Oto-Rhino-Laryngol 2004;261:526-30.
75. Yoshiji H, Kuriyama S, Noguchi R, et al. Angiopoietin 2 displays a vascular endothelial growth factor dependent synergistic effect in hepatocellular carcinoma development in mice. Gut 2005;54:1768-75.
76. Yoshiji H, Kuriyama S, Noguchi R, et al. Amelioration of carcinogenesis and tumor growth in the rat liver by combination of vitamin K2 and angiotensin-converting enzyme inhibitor via anti-angiogenic activities. Oncol Rep 2006;15:155-9.
77. Yoshiji H, Noguchi R, Kuriyama S, et al. Suppression of reninangiotensin system attenuates hepatocarcinogenesis via angiogenesis inhibition in rats. Anticancer Res 2005;25:3335-40.
78. Friis S, Sorensen HT, Mellemkjaer L, et al. Angiotensin-converting enzyme inhibitors and the risk of cancer: a population-based cohort study in Denmark. Cancer 2001;:2462-70.
79. Fryzek J, Poulsen A, Lipworth L, et al. A cohort study of antihypertensive medication use and breast cancer among Danish women. Breast Cancer Res Treat 2006;:231.
80. Li CI, Malone KE, Weiss NS, Boudreau DM, Cushing-Haugen KL, Daling JR. Relation between use of antihypertensive medications and risk of breast carcinoma among women ages 65-79 years [see comment]. Cancer 2003;:1504-13.
81. Largent J, McEligot A, Ziogas A, et al. Hypertension, diuretics and breast cancer risk. J Hum Hypertens 2006;20:727-32.
82. Friis S, Thomassen L, Sorensen HT, et al. Nonsteroidal antiinflammatory drug use and breast cancer risk: a Danish cohort study. Eur J Cancer Prev 2008;17:88-96.
83. Zhang S, Cook N, Manson JE, Lee I, Buring J. Low-dose aspirin and breast cancer risk: results by tumour characteristics from a randomised trial. Br J Cancer 2008;11:989-91.
84. Bennett A. The production of prostanoids in human cancers, and their implications for tumor progression. Prog Lipid Res 1986;25:539-42.
85. Brueggemeier RW, Quinn AL, Parrett ML, Joarder FS, Harris RE, Robertson FM. Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens. Cancer Lett 1999;140:27-35.
86. Hwang D, Scollard D, Byrne J, Levine E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 1998;90:455-60.
87. Alshafie GA, Harris RE, Robertson FM, Parrett ML, Ross M, Abou-Issa H. Comparative chemopreventive activity of ibuprofen and N-(4-hydroxyphenyl) retinamide against the development and growth of rat mammary adenocarcinomas. Anticancer Res 1999;19:3031-6.
88. McCormick DL, Madigan MJ, Moon RC. Modulation of rat mammary carcinogenesis by indomethacin. Cancer Res 1985;45:1803-8.
89. Robertson FM, Parrett ML, Joarder FS, et al. Ibuprofen-induced inhibition of cyclooxygenase isoform gene expression and regression of rat mammary carcinomas. Cancer Lett 1998;122:165-75.
90. Jones MK, Wang H, Peskar BM, et al. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing [see comment]. Nat Med 1999;5:1418-23.
91. Setoguchi S, Glynn RJ, Avorn J, Mogun H, Schneeweiss S. Statins and the risk of lung, breast, and colorectal cancer in the elderly. Circulation 2007;115:27-33.
92. Boudreau DM, Yu O, Miglioretti DL, Buist DS, Heckbert SR, Daling JR. Statin use and breast cancer risk in a large population-based setting. Cancer Epidemiol Biomarkers Prev 2007;16:416-21.
93. Sharpe C, Collet JP, McNutt M, Belzile E, Boivin JF, Hanley J. Nested case-control study of the effects of non-steroidal antiinflammatory drugs on breast cancer risk and stage. Br J Cancer 2000;83:112-20.
94. Harris R, Beebe-Donk J, Alshafie G. Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer 2006;6:27.
95. Harris RE, Namboodiri KK, Stellman SD, Wynder E. Breast cancer and NSAID use: heterogeneity of effect in a case-control study. Prev Med 1995;24:119-20.
96. Swede H, Mirand AL, Menezes RJ, Moysich KB. Association of regular aspirin use and breast cancer risk. Oncology 2005;68:40-7.
97. Zhang Y, Coogan PF, Palmer JR, Strom BL, Rosenberg L. Use of nonsteroidal antiinflammatory drugs and risk of breast cancer: the Case-Control Surveillance Study revisited. Am J Epidemiol 2005;162:165-70.
98. Cotterchio M, Kreiger N, Sloan M, Steingart A. Nonsteroidal antiinflammatory drug use and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2001;10:1213-7.
99. Harris RE, Namboodiri KK, Farrar WB. Nonsteroidal antiinflammatory drugs and breast cancer. Epidemiology 1996;7:203-5.
100. Moorman PG, Grubber J, Millikan RC, Newman B. Association between non-steroidal anti-inflammatory drugs (NSAIDs) and invasive breast cancer and carcinoma in situ of the breast. Cancer Causes Control 2003;14:915-22.
101. Slattery M, Curtin K, Baumgartner R, et al. IL6, aspirin, nonsteroidal anti-inflammatory drugs, and breast cancer risk in women living in the southwestern United States. Cancer Epidemiol Biomarkers Prev 2007;16:747-55.
102. Terry MB, Gammon MD, Zhang F, et al. Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA 2004;291:2433-40.
103. Davis S, Mirick DK. Medication use and the risk of breast cancer. Eur J Epidemiol 2007;22:319-25.
104. Garcia Rodriguez L, Gonzalez-Perez A. Risk of breast cancer among users of aspirin and other anti-inflammatory drugs. Br J Cancer 2004;91:525-9.
105. Harris RE, Chlebowski R, Jackson RD, et al. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. Cancer Res 2003;63:6096-101.
106. Gallicchio L, McSorley M, Newschaffer C, et al. Nonsteroidal antiinflammatory drugs, cyclooxygenase polymorphisms, and the risk of developing breast carcinoma among women with benign breast disease. Cancer 2006;106:1443-52.
107. Gallicchio L, Visvanathan K, Burke A, Hoffman S, Helzlsouer KJ. Nonsteroidal anti-inflammatory drugs and the risk of developing breast cancer in a population-based prospective cohort study in Washington County, MD. Int J Cancer 2007;121:2965-9.
108. Moorman PG, Sesay J, Nwosu V, et al. Cyclooxygenase 2 polymorphisms (Val511Ala), nonsteroidal anti-inflammatory drug use and breast cancer in African American women. Cancer Epidemiol Biomarkers Prev 2005;14:3013-4.
109. Shen J, Gammon MD, Terry M, Teitelbaum SL, Neugut AI, Santella RM. Genetic polymorphisms in the cyclooxygenase-2 gene, use of nonsteroidal anti-inflammatory drugs, and breast cancer risk. Breast Cancer Res 2006;8:R71.
110. Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 1994;5:138-46.
111. Johnson T, Anderson K, Lazovich D, Folsom A. Association of aspirin and nonsteroidal anti-inflammatory drug use with breast cancer. Cancer Epidemiol Biomarkers Prev 2002;11:1586-91.
112. Bardia A, Ebbert JO, Vierkant RA, et al. Association of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs with cancer incidence and mortality. J Natl Cancer Inst 2007;99:881-9.
113. Harris R, Kasbari S, Farrar WB. Prospective study of nonsteroidal anti-inflammatory drugs and breast cancer. Oncol Rep 1999;6:71-3.
114. Ready A, Velicer CM, McTiernan A, White E. NSAID use and breast cancer risk in the VITAL cohort. Breast Cancer Res Treat 2007;:11.
115. Jacobs EJ, Thun MJ, Connell C, et al. Aspirin and other nonsteroidal anti-inflammatory drugs and breast cancer incidence in a large US cohort. Cancer Epidemiol Biomarkers Prev 2005;14:261-4.
116. Marshall S, Bernstein L, Anton-Culver H, et al. Nonsteroidal antiinflammatory drug use and breast cancer risk by stage and hormone receptor status. J Natl Cancer Inst 2005;97:805-12.
117. Egan K, Stampfer MJ, Giovannucci EL, Rosner B, Colditz GA. Prospective study of regular aspirin use and the risk of breast cancer. J Natl Cancer Inst 1996;88:988-93.
118. Cook N, Lee I, Gaziano J, et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005;294:47-55.
119. Jacobs E, Thun MJ, Bain E, Rodriguez C, Henley SJ, Calle EE. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst 2007;99:608-15.
120. Khuder S, Mutgi A. Breast cancer and NSAID use: a meta-analysis. Br J Cancer 2001;84:1188-92.
121. Mangiapane S, Blettner M, Schlattmann P. Aspirin use and breast cancer risk: a meta-analysis and meta-regression of observational studies from 2001 to 2005. Pharmacoepidemiol Drug Saf 2008;17:115-24.
122. Gonzalez-Perez A, Garcia Rodriguez L, Lopez-Ridaura R. Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis. BMC Cancer 2003;3:28.
123. Zhang J, Ding EL, Song Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials [see comment]. JAMA 2006;296:1619-32.
124. Kaye JA, Jick H. Antibiotics and the risk of breast cancer. Epidemiology 2005;:688-90.
125. Didham RC, Reith DM, McConnell DW, Harrison KS. Antibiotic exposure and breast cancer in New Zealand. Breast Cancer Res Treat 2005;:163.
126. Kaye JA, Jick H. Statin use and cancer risk in the General Practice Research Database. Br J Cancer 2004;:635-7.
127. Graaf MR, Beiderbeck AB, Egberts ACG, Richel DJ, Guchelaar H-J. The risk of cancer in users of statins. J Clin Oncol 2004;2388-94.
128. Meier CR, Schmitz S, Jick H. Association between acetaminophen or nonsteroidal antiinflammatory drugs and risk of developing ovarian, breast, or colon cancer. Pharmacotherapy 2002;22:303-9.
129. Rahme E, Ghosn J, Dasgupta K, Rajan R, Hudson M. Association between frequent use of nonsteroidal anti-inflammatory drugs and breast cancer. BMC Cancer 2005;5:159.